

- The most common ADRs seen with KADCYLA in EMILIA (frequency > 25%) were nausea, fatigue, musculoskeletal pain, thrombocytopenia, increased transaminases, headache, and constipation. The most common NCI-CTCAE (version 3) \geq Grade 3 ADRs (frequency > 2%) were thrombocytopenia, increased transaminases, anemia, hypokalemia, peripheral neuropathy and fatigue

You are encouraged to report side effects to Genentech and the FDA. You may contact Genentech by calling **1 (888) 835-2555**. You may contact the FDA by visiting **www.fda.gov/medwatch** or calling **1 (800) FDA-1088**.

Please see accompanying full Prescribing Information for additional important safety information, including Boxed WARNINGS.

References: 1. KADCYLA Prescribing Information. Genentech, Inc. May 2013. 2. Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hassmann M. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. *Cancer Res.* 2009;69:9330-9336.

Genentech
A Member of the Roche Group

[Home](#) | [Contact Us](#) | [Site Map](#) | [Important Safety Information](#) | [Privacy Policy](#) | [Terms and Conditions](#)

© 2013 Genentech USA, Inc. All rights reserved.
This site is intended for US residents only.

Updated video -
TDM0001424701

Proposed MOA

Indication
KADCYLA[®] [ado-trastuzumab emtansine], as a single agent, is indicated for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either¹:

- Received prior therapy for metastatic disease, or
- Developed disease recurrence during or within six months of completing adjuvant therapy

©flowplayer

00:11 07:10

SELECT A VIDEO

Animated MOA



MOA Video with Audio

